Brief Summary
Individual patient expanded access requests may be considered for patients who have no other treatment options
Detailed Description
Expanded access may provide access for treatment prior to approval by the local regulatory agency. For full details, please visit the link provided.
Available
Individual Patients
X-linked Hypophosphatemia
Tumor-Induced Osteomalacia
Biological: Burosumab
Other Name: UX023
Other Name: Crysvita®
Other Name: KRN23
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Eligibility Gender
All
Contacts
Early Access
1-415-483-8800
EarlyAccess@ultragenyx.com
Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.
NCT Number
Keywords
Expanded Access
Compassionate Use
XLH
TIO
MeSH Terms
Familial Hypophosphatemic Rickets
Osteomalacia
Hypophosphatemia